LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

Kodu・Aktsiate loetelu・Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics Inc

Suletud

SektorTervishoid

26.91 2.44

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

26.13

Max

27.01

Põhinäitajad
By Trading Economics
Sissetulek	23M 7.4M
Müük	18M 99M
Aktsiakasum	0.06
Kasumimarginaal	7.468
Töötajad	342
EBITDA	23M 11M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+25.89% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	25. veebr 2026

Turustatistika
By TradingEconomics
Turukapital	756M 3.2B
Eelmine avamishind	24.47
Eelmine sulgemishind	26.91

Uudiste sentiment

By Acuity

45%

55%

134 / 351 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

12.42 / 14.93 Toetus ja vastupanu

Arcutis Biotherapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

23. veebr 2026, 22:53 UTC

Omandamised, ülevõtmised, äriostud

Keurig Dr Pepper Raises Additional $1.5 Billion in Deal to Split Company

23. veebr 2026, 22:36 UTC

Tulu

Kratos Defense & Security Solutions 4Q Profit Rises; Sees Federal Shutdown Denting 1Q -- Update

23. veebr 2026, 22:32 UTC

Tulu

Woodside Energy Fiscal Year Net Profit Falls 24%

23. veebr 2026, 23:58 UTC

Market Talk

Tulu

Plenty of Questions for Woodside Despite Well-Guided Result -- Market Talk

23. veebr 2026, 23:58 UTC

Market Talk

Tulu

Global Energy Roundup: Market Talk

23. veebr 2026, 23:47 UTC

Market Talk

Scentre's Share Price Slips as Earnings Guidance Underwhelms -- Market Talk

23. veebr 2026, 23:43 UTC

Market Talk

Gold Edges Higher Amid Ongoing Tariff Risks -- Market Talk

23. veebr 2026, 23:41 UTC

Omandamised, ülevõtmised, äriostud

Crescent Capital Partners Owns 53% of ClearView Wealth

23. veebr 2026, 23:40 UTC

Omandamised, ülevõtmised, äriostud

ClearView Wealth Says Crescent Capital Partners Intends to Support Deal

23. veebr 2026, 23:40 UTC

Omandamised, ülevõtmised, äriostud

ClearView Wealth Says Directors Unanimously Recommend Shareholders Vote in Favor of Deal

23. veebr 2026, 23:40 UTC

Market Talk

Nikkei May Rise as Investors Assess Tariff Developments -- Market Talk

23. veebr 2026, 23:40 UTC

Omandamised, ülevõtmised, äriostud

ClearView Wealth Says Zurich Insurance Offering A$0.65/Share in Cash

23. veebr 2026, 23:39 UTC

Omandamised, ülevõtmised, äriostud

ClearView Wealth Agrees to Takeover by Zurich Insurance Group Unit

23. veebr 2026, 23:31 UTC

Tulu

United Overseas Bank 2025 Total Dividend S$1.56/Shr >U11.SG

23. veebr 2026, 23:31 UTC

Tulu

United Overseas Bank Proposes Final Dividend of S$0.71/Shr Vs. S$0.92/Shr >U11.SG

23. veebr 2026, 23:28 UTC

Tulu

United Overseas Bank 4Q Net Interest Income S$2.35B Vs. S$2.45B >U11.SG

23. veebr 2026, 23:28 UTC

Tulu

United Overseas Bank 4Q Oper Pft S$1.76B Vs. Pft S$1.88B >U11.SG

23. veebr 2026, 23:28 UTC

Tulu

United Overseas Bank 4Q Total Income S$3.29B Vs. S$3.46B >U11.SG

23. veebr 2026, 23:27 UTC

Tulu

United Overseas Bank 4Q Net S$1.41B Vs. Net S$1.52B >U11.SG

23. veebr 2026, 23:24 UTC

Market Talk

Major Miners On Whole Delivered Positive Earnings Season -- Market Talk

23. veebr 2026, 22:38 UTC

Omandamised, ülevõtmised, äriostud

Keurig Dr Pepper Raises Additional $1.5B in Deal to Split Company

23. veebr 2026, 22:31 UTC

Tulu

Hims & Hers Stock Falls. Why Earnings Are Underwhelming Investors. -- Barrons.com

23. veebr 2026, 22:24 UTC

Tulu

Viva Energy Energy & Infrastructure Ebitda A$93 Million

23. veebr 2026, 22:22 UTC

Tulu

Viva Energy FY Commercial & Industrial Ebitda A$460.5 Million

23. veebr 2026, 22:22 UTC

Tulu

Viva Energy FY Convenience & Mobility Ebitda A$197.4 Million

23. veebr 2026, 22:22 UTC

Tulu

Viva Energy FY Underlying Ebitda A$700.9 Million

23. veebr 2026, 22:22 UTC

Tulu

Viva Energy Final Dividend 3.94 Australian Cents/Security

23. veebr 2026, 22:21 UTC

Tulu

Viva Energy FY Revenue A$28.53 Billion, Down 1.1%

23. veebr 2026, 22:21 UTC

Tulu

Viva Energy FY Replacement-Cost Net Profit A$183.6 Million, Down 28%

23. veebr 2026, 22:20 UTC

Tulu

Viva Energy FY Historical-Cost Net Loss A$421.1 Million

Võrdlus sarnastega

Hinnamuutus

Arcutis Biotherapeutics Inc Prognoos

Hinnasiht

By TipRanks

25.89% tõus

12 kuu keskmine prognoos

Keskmine 32 USD 25.89%

Kõrge 37 USD

Madal 30 USD

Põhineb 7 Wall Streeti analüütiku instrumendi Arcutis Biotherapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

7 ratings

Osta

Hoia

Müü

Põhineb 7 analüütiku instrumendi Arcutis Biotherapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

12.42 / 14.93Toetus ja vastupanu

Recent bearish events outweigh bullish events.

There is one bullish event.

Sentiment

By Acuity

134 / 351 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.